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Abstract 
 
INTRODUCTION: Machine learning (ML) may harbor the potential to capture 
the metabolic complexity in Alzheimer’s Disease (AD). Here we set out to test 
the performance of metabolites in blood to categorise AD when compared to 
CSF biomarkers. 
 
METHODS: This study analysed samples from 242 cognitively normal (CN) 
people and 115 with AD-type dementia utilizing plasma metabolites (n=883). 
Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random 
Forest (RF) were used to differentiate AD from CN. These models were 
internally validated using Nested Cross Validation (NCV). 
 
RESULTS: On the test data, DL produced the AUC of 0.85 (0.80-0.89), 
XGBoost produced 0.88 (0.86-0.89) and RF produced 0.85 (0.83-0.87). By 
comparison, CSF measures of amyloid, p-tau and t-tau (together with age and 
gender) produced with XGBoost the AUC values of 0.78, 0.83 and 0.87, 
respectively. 
 
DISCUSSION: This study showed that plasma metabolites have the potential 
to match the AUC of well-established AD CSF biomarkers in a relatively small 
cohort. Further studies in independent cohorts are needed to validate whether 
this specific panel of blood metabolites can separate AD from controls, and how 
specific it is for AD as compared with other neurodegenerative disorders 
 
  
  
1. Introduction 
 
At present, the diagnosis of Alzheimer’s disease–type dementia (AD) is based 
on protein biomarkers in cerebrospinal fluid (CSF) and brain imaging together 
with a battery of cognition tests. Diagnostic tools based on CSF collection are 
invasive while brain-imaging tools are still costly, and therefore, there is a need 
to identify non-invasive tools for early detection as well as for measuring 
disease progression. 
 
In recent years, an increasing number of studies have examined blood 
metabolites as potential AD biomarkers [1-4]. The advantages of looking at 
blood metabolites are that they are easily accessible but also that they 
represent an essential aspect of the phenotype of an organism and hence might 
act as a molecular fingerprint of disease progression [5, 6]. Therefore, blood 
AD markers could potentially aid early diagnosis and recruitment for trials. 
 
Here we utilised data generated as part of the European Medical Information 
Framework for AD Multimodal Biomarker Discovery (EMIF-AD) previously 
reported in full in Kim et al [8]. As discussed in that paper, metabolite levels 
were measured using liquid chromatography–mass spectroscopy (LC-MS) to 
cover ca. 800 metabolites and these metabolites related to CSF biomarkers of 
AD commonly used in clinical research including trials, and increasingly in 
clinical practice, as part of the diagnostic work up. Here we explore the potential 
of different machine Learning (ML) algorithms to identify those individuals with 
AD from dataset and to compare the effectiveness of blood based metabolites 
as an indicator of clinical diagnosis to that of CSF markers. In this study we 
employed two state of the art ML algorithms - Deep Learning (DL) and Extreme 
Gradient Boosting (XGBoost) - and compared these to the more commonly 
utilized Random Forest (RF) algorithm.   
  
2. Methods 
 
This study accessed data previously generated from 242 samples from 
cognitively normal (CN) individuals and 115 from people with AD-type dementia 
(AD) samples in which diagnosis was based on clinical diagnosis. Details on 
the subjects, clinical and cognitive data as well as measurements of AD 
pathological markers have been described elsewhere [7, 8]. The metabolomics 
data employed here was accessed in the EMIF-AD portal and the acquisition 
and processing details can be found via open access in [8]. In short, the EMIF-
AD cohort is a collated cohort making use of existing data and samples 
collected in 11 different studies across Europe, with the aim to discover novel 
diagnostic and prognostic markers for predementia AD.  
 
In the current study, the main objective was to use state of the art ML 
classification algorithms to build CN vs AD predictive models using blood 
metabolites. For this purpose, we employed DL and XGBoost. Additionally we 
also employed the more popularly used RF) algorithm. These models were 
compared in terms of binary classifiers with Area Under the Curve (AUC) in 
Receiver Operating Characteristic (ROC) curves. 
 
The metabolites with more than 45% missing values were discarded. The 
remaining missing values were handled with imputation methods based on the 
k-nearest neighbour (RF and DL), or internally by the classification algorithm 
(XGBoost). Models were built and evaluated using a Nested Cross Validation 
(NCV) which used 9/10 data folds for model training and optimisation in an inner 
cross validation, and 1/10 data folds for model testing in an outer cross 
validation. The process was repeated 10 times, for each of the test data folds. 
 
The analysis was further extended by assessing the stability of the AUC 
performance with Monte Carlo (MC) simulations consisting of 50 repeated 
similar NCV experiments. As such, multiple models were built on multiple 
samples in the NCV and MC, using metabolite predictors selected on the basis 
of their capability to discriminate CN vs AD as measured by the Relief algorithm 
[9] applied on training data in combination with 500 permutations of the 
  
outcome variable’s values. This method computes the predictors’ importance 
defined as the standardised Relief score, according to Measuring Predictor 
Importance chapter of [10]. Part of the prediction modelling methodology in this 
study was adapted after [11], with different algorithms, and followed 
recommendations from [10, 12]. The analysis was carried out using R software 
[13]. Pathway analysis was performed on the top 20 ranked metabolites using 
MetaboAnalyst 4.0 [14]. The algorithms were run on four servers with 6-core 
Xeon CPUs and 336 GB RAM. 
  
  
3. Results 
 
In this study, we analysed metabolite data derived from blood samples from 
357 participants (CN n=242, AD n=115) previously reported in Kim et al [8]. 
Demographic and clinical data can be found in [8]; in short, there was no 
difference in gender while AD participants were older when compared with CN 
participants.  
 
On the test data, the DL model produced a Receiver Operating Characteristic 
(ROC) Area Under the Curve (AUC) value of 0.85 with its 95% confidence 
interval (CI) ranging between [0.8038, 0.8895].  The XGBoost model produced 
the AUC value of 0.88 (95% CI [0.8619, 0.8903]). When the classifier model RF 
was employed, the resulting AUC was 0.85 (95%CI  [0.8323, 0.8659]). Fig. 1 
illustrates ROC curves obtained from the three ML models. 
 
The MC simulation conducted with XGBoost which was the superior predictive 
model in our analysis, led to a Gaussian distribution of the AUC values 
according to [11] and as confirmed by Shapiro-Wilk test (p-value=0.6819). The 
50 AUC values obtained in MC had a minimum of 0.8614, a maximum of 
0.8923, a mean of 0.8761, a median of 0.8766, and a standard deviation of 
0.0072. The t-test showed that the true mean of AUC for XGBoost applied on 
plasma metabolites was not lower than 0.87 (p-value=1.265X10-07). 
  
For comparison, we also investigated the levels of amyloid, p-tau and t-tau, to 
which we added also age and gender, and their prediction for clinical AD vs 
CN. XGBoost models were built in the same manner as for metabolite 
predictors. Together with age and gender, amyloid led to AUC 0.78 (95%CI 
[0.7626, 0.8013]); p-tau led to AUC 0.83 (95%CI [0.8188, 0.8470]); and t-tau 
led to AUC 0.87 (95%CI [0.8583, 0.8854]). From the mean AUC for metabolites 
and for amyloid, p-tau and t-tau calculated individually, the t-tests showed 
superior values for metabolites (p-value<2.2X10-16, p-value<2.2X10-16, and p-
value=0.005921, respectively).  
 
 
  
 
 
Figure 1. Shows the AUC values for the XGBoost, RF and DL models. 
XGBoost performed best with metabolite predictors in the EMIF cohort. 
 
The top 20 ranked predictors out of the 347 selected by the method presented 
in the previous section, are shown in Fig. 2.   
 
 
Figure 2.  The x-axis shows the top 20 ranked predictors,  and the y-axis 
shows the predictors’ importance computed as the standardised Relief score 
according to Measuring Predictor Importance chapter of [10]. 
 
  
Pathway analyses revealed that the Nitrogen pathway was overrepresented 
(qFDR=0.004) within the panel. Molecules that were captured as the 20 top 
ranking predictors are discussed in the next section. 
 
 
  
  
4. Discussion 
 
Machine Learning applied to healthcare is increasingly enabled by the advent 
of high-performance computing and the development of complex algorithms. In 
this study, we employed two state of the art algorithms, DL and XGBoost, and 
a more conventional algorithm, RF, to obtain high accuracy models to predict 
AD vs CN with metabolites as predictors. Our study showed that the best model 
was based on XGBoost [15] which is an enhanced form of Gradient Boosting 
Machines methods based on decision trees [12]. In our study RF and DL 
achieved comparable AUC. DL algorithms are known to often take advantage 
of large and/or unstructured data (such as images) to produce more accurate 
category discrimination/ prediction. In a study using the Alzheimer's Disease 
Neuroimaging Initiative (ADNI) data for AD prediction, XGBoost demonstrated 
superior results (AUC= 0.97 (0.01)) when including imaging parameters (MRI 
and PET) as predictors and when compared to RF, Support Vector Machines, 
Gaussian Processes and Stochastic Gradient Boosting [16]. In other study 
where cognition and MRI were used as predictors, Kernel Ridge Regression 
performed to R2=0.87 (0.025) when cognition and MRI predictors were included 
[17]. 
 
Pathway analyses using the top 20 AD predicting metabolites derived from the 
Relief method showed that the Nitrogen pathway was overrepresented. Some 
of the molecules selected have been reported in metabolomics studies and 
have been implicated in neurodegeneration: Dodecanate, which is a C12 fatty 
acid, was found correlated to longitudinal measures of cognition in the ADNI 
cohort [3] and so was the bile acid glycolithocholate which was associated to 
both AD and cognition measures (ADAS-Cog13) in one of the biggest cross-
sectional studies on cognition, AD and the microbiome [18]. Plasmalogens 
were also found in decreased levels in our cohort in agreement with an earlier 
report [19]. The amide form of vitamin B3, nicotamide, has been implicated in 
both neuroprotection and neuronal death [20]. 
 
New metabolites that could be of interest and have not been previously reported 
as related to AD were phytanate and furoylglycine. The former is a known 
  
neurotoxin which impairs mitochondrial function and transcription [21]. 
Furoylglycine is a metabolite which, as lithocholic acid, is mainly synthesized 
by the microbiome and has been reported as a biomarker of coffee 
consumption [22]. 
 
A limitation of our study is that it does not include an external validation due to 
the size of the cohort. However, we implemented a NCV procedure repeated 
50 times in a MC simulation that led to an extended internal validation with 
prediction accuracy of cases. Further studies will assess the performance of 
ratios/combinations of CSF markers and metabolites, life-style factors and 
disorders commonly found in the elderly, together with testing the specificity for 
this specific panel in other neurodegenerative (e.g. PD, FTD), neurological (e.g. 
stroke) and psychiatric (e.g. depression) disorders associated with aging. 
 
The intent of this paper was to compare the performance of different ML 
algorithms to identify people with AD from cognitively unimpaired individuals. 
Here we show first that all three approaches used demonstrate good 
discriminatory power, second that XGBoost is somewhat more effective in this 
particular dataset than RF and DL and third, that this accuracy for clinical 
diagnosis is broadly similar to that achieved by CSF markers of AD pathology. 
The lack of a replication and validation dataset limits the interpretation of this 
finding but nonetheless the strong prediction of diagnostic category from a 
blood based metabolite biomarker set is further evidence of the potential of 
such approaches to complement other biomarkers in identification of people 
with likely AD 
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